Please assess the completion status of the following clinical trial:

Trial Title: XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have successfully completed one of the following studies: XP052 (110963 \[NCT00298623\]), XP053 (111460 \[NCT00365352\]), XP081 (111462 \[NCT01332305\]), and XP083 (111463 \[NCT01332318\]).~Exclusion Criteria:~* Subjects who, in the opinion of the Investigator, would be non-compliant with the study visit schedule, procedures, or medication administration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- XP13512 (GEn) (Type: EXPERIMENTAL): 1200 mg XP13512, orally, once daily for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).